



## **Disclosure of Transfers of value to HCPs/HCOs**

### **2024 Self-Certification**

Healthcare professionals (HCPs) and healthcare organisations (HCOs) with whom Angelini Pharma Nordics AB (“Angelini Pharma”) works, provide the Pharmaceutical Industry with valuable, independent and expert knowledge derived from their clinical and management experience. As owners of scientific knowledge and experts in medicinal products, pharmaceutical companies can be a unique resource to the healthcare systems and providers, which will ultimately benefit the patients.

Throughout the medicines life cycle, pharmaceutical companies work with scientists and HCPs. These collaborations are essential in addressing patient needs. Industry and HCPs collaborate in a range of activities from clinical research to sharing best clinical practice and exchanging information on how new medicines fit into the patient pathway.

*Pharma Industry Finland (PIF)* - as member of EFPIA - has adopted codes and guidelines to ensure that the interactions of their member companies with HCPs and HCOs meet the high standards of integrity and transparency. Building greater transparency to the relationships between pharmaceutical companies and HCPs/HCOs aims to building understanding of the collaboration and recognition of its value to patient care.

EFPIA and its members are fully committed to implement and apply the highest ethical standards.

Angelini Pharma hereby confirms that its disclosures of transfers of value (ToVs) to HCPs and HCOs made in 2023 have been reported in application of the *PIF* Code of Ethics following key principles:

#### **Disclosure quality**

Angelini Pharma certifies that:

- its disclosures are made in *Finland*;
- its disclosure includes direct and indirect ToVs, as defined in the codes and associated guidance issued by *PIF*;
- cross-border ToVs made by the other Angelini Pharma Countries are disclosed as communicated, in accordance with *PIF Code of Ethics*;
- cross-border ToVs to Recipients abroad are communicated to the other Angelini Pharma Countries, in accordance with *PIF Code of Ethics*;
- its Methodological Note describes the process it has followed in order to compile the data hereby disclosed.

**Methodology used for the collection and organisation of ToVs is in line with the *PIF* Code of Ethics requirements and applicable codes.**

Angelini Pharma certifies that:

- Data collection complies with the requirements of the *PIF* Code of Ethics;
- Actions are taken to ensure individual disclosure for HCPs and HCOs’ transfers of values (each as defined in the *PIF* Code of Ethics).

**Aggregate disclosures are limited to Research and Development ToVs and such ToVs that cannot be disclosed on an individual basis for legal reasons.**



Angelini Pharma certifies that aggregate disclosure is limited to the following topics:

- Research and Development Transfers of Value (as defined in the *PIF* Code of Ethics);
- Transfers of Value to Recipients that have opposed to the publication on grounds of the protection of their private data;
- If an HCP has provided consent to individual disclosure only in respect of part of the Transfers of Value he/she/it received, all Transfers of Value to such HCP are being disclosed in the aggregate.

### Ensuring compliance with Data Privacy Obligations


Angelini Pharma certifies that the collection, processing and disclosure of transfers of value have been made in accordance with Data Privacy obligations.

**Date:** 14-Jun-2024 | 04:18 EDT

**Name of signatory:** Fräs Anna Andersson

**Position in the Company:** Country Director Nordics

**Signature:**

DocuSigned by:  
  
31C4CE44DB9E450...